Peptide-Based Nanovaccines in the Treatment of Cervical Cancer: A Review of Recent Advances

References

• Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013;382(9895):889–899. doi:10.1016/S0140-6736(13)60022-7
   PubMed Web of Science ®Google Scholar
• Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–19.
   PubMed Web of Science ®Google Scholar
• Pal A, Kundu R. Human papillomavirus E6 and E7: the cervical cancer hallmarks and targets for therapy. Front Microbiol. 2019;10:3116.
   PubMed Web of Science ®Google Scholar
• Prat J. Pathology of cancers of the female genital tract. Int J Gynecol Obstet. 2015;131:S132–S145.
   PubMed Web of Science ®Google Scholar
• Cervical cancer treatment. Cellular classification of cervical cancer; 2020. Available from: https://www.cancer.gov/types/cervical/hp/cervical-treatment-pdq#link/_405_toc. Accessed September 3, 2020.
   Google Scholar
• Zepp F. Principles of vaccine design-Lessons from nature. Vaccine. 2010;28(Suppl 3):C14–24.
   PubMed Web of Science ®Google Scholar
• Toussaint B, Chauchet X, Wang Y, Polack B, Le Gouellec A. Live-attenuated bacteria as a cancer vaccine vector. Expert Rev Vaccines. 2013;12(10):1139–1154.
   PubMed Web of Science ®Google Scholar
• Kelly HG, Kent SJ, Wheatley AK. Immunological basis for enhanced immunity of nanoparticle vaccines. Expert Rev Vaccines. 2019;18(3):269–280.
   PubMed Web of Science ®Google Scholar
• Castle PE, Maza M. Prophylactic HPV vaccination: past, present, and future. Epidemiol Infect. 2016;144(3):449–468.
   PubMed Web of Science ®Google Scholar
• Hancock G, Hellner K, Dorrell L. Therapeutic HPV vaccines. Best Pract Res Clin Obstet Gynaecol. 2018;47:59–72. doi:10.1016/j.bpobgyn.2017.09.008
   PubMed Web of Science ®Google Scholar
• Hung C-F, Ma B, Monie A, Tsen S-W, Wu T-C. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther. 2008;8(4):421–439. doi:10.1517/14712598.8.4.421
   PubMed Web of Science ®Google Scholar
• Wang R, Pan W, Jin L, et al. Human papillomavirus vaccine against cervical cancer: opportunity and challenge. Cancer Lett. 2020;471:88–102. doi:10.1016/j.canlet.2019.11.039
   PubMed Web of Science ®Google Scholar
• Liu T-Y, Hussein WM, Toth I, Skwarczynski M. Advances in peptide-based human papillomavirus therapeutic vaccines. Curr Top Med Chem. 2012;12(14):1581–1592. doi:10.2174/156802612802652402
   PubMed Web of Science ®Google Scholar
• Paston SJ, Brentville VA, Symonds P, Durrant LG. Cancer vaccines, adjuvants, and delivery systems. Front Immunol. 2021;12:627932. doi:10.3389/fimmu.2021.627932
   PubMed Web of Science ®Google Scholar
• Skwarczynski M, Toth I. Peptide-based synthetic vaccines. Chem Sci. 2016;7(2):842–854. doi:10.1039/C5SC03892H
   PubMed Web of Science ®Google Scholar
• Azuar A, Jin J, Mukaida M, et al. Recent advances in the development of peptide vaccines and their delivery systems against group A Streptococcus. Vaccines. 2019;7(3):58. doi:10.3390/vaccines7030058
   Web of Science ®Google Scholar
• Skwarczynski M, Toth I. Recent advances in peptide-based subunit nanovaccines. Nanomedicine. 2014;9(17):2657–2669.
   PubMed Web of Science ®Google Scholar
• Al-Halifa S, Gauthier L, Arpin D, Bourgault S, Archambault D. Nanoparticle-based vaccines against respiratory viruses. Front Immunol. 2019;10:22.
   PubMed Web of Science ®Google Scholar
• Deivendran S, Marzook KH, Radhakrishna pillai M. The role of inflammation in cervical cancer. Adv Exp Med Biol. 2014;816:377–399.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191–e203.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Buskwofie A, David-West G, Clare CA. A review of cervical cancer: incidence and disparities. J Natl Med Assoc. 2020;112(2):229–232.
   PubMed Web of Science ®Google Scholar
• Mboumba Bouassa RS, Prazuck T, Lethu T, et al. Cervical cancer in sub-Saharan Africa: a preventable noncommunicable disease. Expert Rev Anti Infect Ther. 2017;15(6):613–627.
   PubMed Web of Science ®Google Scholar
• Canfell K, Kim JJ, Brisson M, et al. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395(10224):591–603.
   PubMed Web of Science ®Google Scholar
• Small W Jr., Bacon MA, Bajaj A, et al. Cervical cancer: a global health crisis. Cancer. 2017;123(13):2404–2412.
   PubMed Web of Science ®Google Scholar
• Sadri NJ, Moghoofei M, Salmaninejad A, et al. Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: a review. Int J Cancer. 2019;146(2):305–320.
   PubMed Web of Science ®Google Scholar
• Shrestha AD, Neupane D, Vedsted P, Kallestrup P. Cervical cancer prevalence, incidence and mortality in low and middle income countries: a systematic review. Asian Pac J Cancer Prev. 2018;19(2):319–324.
   PubMedGoogle Scholar
• Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2018: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2018;68(4):297–316.
   PubMed Web of Science ®Google Scholar
• Yim EK, Park JS. The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis. Cancer Res Treat. 2005;37(6):319–324.
   PubMedGoogle Scholar
• Arbyn M, Castellsague X, de Sanjose S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22(12):2675–2686.
   PubMed Web of Science ®Google Scholar
• Kiatpongsan S, Kim JJ. Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two East African countries. PLoS One. 2014;9(9):e106836.
   PubMed Web of Science ®Google Scholar
• Fang J, Zhang H, Jin S. Epigenetics and cervical cancer: from pathogenesis to therapy. Tumour Biol. 2014;35(6):5083–5093.
   PubMedGoogle Scholar
• Yang A, Jeang J, Cheng K, et al. Current state in the development of candidate therapeutic HPV vaccines. Expert Rev Vaccines. 2016;15(8):989–1007.
   PubMed Web of Science ®Google Scholar
• Ngoma M, Autier P. Cancer prevention: cervical cancer. Ecancermedicalscience. 2019;13:952.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017–Recommendations. Vaccine. 2017;35(43):5753–5755.
   PubMed Web of Science ®Google Scholar
• Harper DM, DeMars LR. HPV vaccines – a review of the first decade. Gynecol Oncol. 2017;146(1):196–204.
   PubMed Web of Science ®Google Scholar
• Pinto LA, Edwards J, Castle PE, et al. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis. 2003;188(2):327–338.
   PubMed Web of Science ®Google Scholar
• Harro CD, Pang YY, Roden RB, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst. 2001;93(4):284–292.
   PubMed Web of Science ®Google Scholar
• Ghittoni R, Accardi R, Chiocca S, Tommasino M. Role of human papillomaviruses in carcinogenesis. Ecancermedicalscience. 2015;9:526.
   PubMed Web of Science ®Google Scholar
• Zhai L, Tumban E. Gardasil-9: a global survey of projected efficacy. Antiviral Res. 2016;130:101–109.
   PubMed Web of Science ®Google Scholar
• Luckett R, Feldman S. Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancer. Hum Vaccin Immunother. 2016;12(6):1332–1342.
   PubMed Web of Science ®Google Scholar
• Poljak M. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges. Clin Microbiol Infect. 2012;18(Suppl 5):64–69.
   PubMed Web of Science ®Google Scholar
• Madrid-Marina V, Torres-Poveda K, Lopez-Toledo G, Garcia-Carranca A. Advantages and disadvantages of current prophylactic vaccines against HPV. Arch Med Res. 2009;40(6):471–477.
   PubMed Web of Science ®Google Scholar
• Burk RD, Harari A, Chen Z. Human papillomavirus genome variants. Virology. 2013;445(1):232–243.
   PubMed Web of Science ®Google Scholar
• Hu Z, Ma D. The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications. Cancer Med. 2018;7(10):5217–5236.
   PubMed Web of Science ®Google Scholar
• Harden ME, Munger K. Human papillomavirus molecular biology. Mutat Res Rev Mutat Res. 2017;772:3–12.
   PubMed Web of Science ®Google Scholar
• Zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology. 2009;384(2):260–265.
   PubMed Web of Science ®Google Scholar
• Doorbar J, Quint W, Banks L, et al. The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30(Suppl 5):F55–70.
   PubMed Web of Science ®Google Scholar
• Panczyszyn A, Boniewska-Bernacka E, Glab G. Telomeres and telomerase during human papillomavirus-induced carcinogenesis. Mol Diagn Ther. 2018;22(4):421–430.
   PubMed Web of Science ®Google Scholar
• Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–527.
   PubMed Web of Science ®Google Scholar
• Stanley M. Pathology and epidemiology of HPV infection in females. Gynecol Oncol. 2010;117(2 Supplement):S5–S10.
   PubMed Web of Science ®Google Scholar
• Graham Sheila V. The human papillomavirus replication cycle, and its links to cancer progression: a comprehensive review. Clin Sci. 2017;131(17):2201–2221.
   Web of Science ®Google Scholar
• Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16(1):1–17.
   PubMed Web of Science ®Google Scholar
• Chang YE, Laimins LA. Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J Virol. 2000;74(9):4174–4182.
   PubMed Web of Science ®Google Scholar
• Egawa N, Doorbar J. The low-risk papillomaviruses. Virus Res. 2017;231:119–127.
   PubMed Web of Science ®Google Scholar
• Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. Human papillomavirus molecular biology and disease association. Rev Med Virol. 2015;25(Suppl 1):2–23.
   PubMed Web of Science ®Google Scholar
• Zheng ZM, Baker CC. Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci. 2006;11:2286–2302.
   PubMed Web of Science ®Google Scholar
• Prati B, Marangoni B, Boccardo E. Human papillomavirus and genome instability: from productive infection to cancer. Clinics. 2018;73:e539s.
   PubMed Web of Science ®Google Scholar
• Yeo-Teh NSL, Ito Y, Jha S. High-risk human papillomaviral oncogenes E6 and E7 target key cellular pathways to achieve oncogenesis. Int J Mol Sci. 2018;19(6):1706.
   PubMed Web of Science ®Google Scholar
• Graham SV. Human papillomavirus: gene expression, regulation and prospects for novel diagnostic methods and antiviral therapies. Future Microbiol. 2010;5(10):1493–1506.
   PubMed Web of Science ®Google Scholar
• Xue J, Vesper BJ, Radosevich JA. Proteins encoded by the human papillomavirus genome and their functions. In: Radosevich JA, editor. HPV and Cancer. Dordrecht: Springer; 2012.
   Google Scholar
• Finnen RL, Erickson KD, Chen XS, Garcea RL. Interactions between papillomavirus L1 and L2 capsid proteins. J Virol. 2003;77(8):4818–4826.
   PubMed Web of Science ®Google Scholar
• Wang JW, Roden RB. L2, the minor capsid protein of papillomavirus. Virology. 2013;445(1–2):175–186.
   PubMed Web of Science ®Google Scholar
• Ibeanu OA. Molecular pathogenesis of cervical cancer. Cancer Biol Ther. 2011;11(3):295–306.
   PubMed Web of Science ®Google Scholar
• Doorbar J. The E4 protein; structure, function and patterns of expression. Virology. 2013;445(1–2):80–98.
   PubMed Web of Science ®Google Scholar
• Venuti A, Paolini F, Nasir L, et al. Papillomavirus E5: the smallest oncoprotein with many functions. Mol Cancer. 2011;10:140.
   PubMed Web of Science ®Google Scholar
• Hwang ES, Nottoli T, Dimaio D. The HPV16 E5 protein: expression, detection, and stable complex formation with transmembrane proteins in COS cells. Virology. 1995;211(1):227–233.
   PubMed Web of Science ®Google Scholar
• Hoppe-Seyler K, Bossler F, Braun JA, Herrmann AL, Hoppe-Seyler F. The HPV E6/E7 oncogenes: key factors for viral carcinogenesis and therapeutic targets. Trends Microbiol. 2018;26(2):158–168.
   PubMed Web of Science ®Google Scholar
• Thomas M, Pim D, Banks L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene. 1999;18(53):7690–7700.
   PubMed Web of Science ®Google Scholar
• Martinez-Zapien D, Ruiz FX, Poirson J, et al. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53. Nature. 2016;529(7587):541–545.
   PubMed Web of Science ®Google Scholar
• Nomine Y, Masson M, Charbonnier S, et al. Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis. Mol Cell. 2006;21(5):665–678.
   PubMed Web of Science ®Google Scholar
• Kuss-Duerkop SK, Westrich JA, Pyeon D. DNA tumor virus regulation of host DNA methylation and its implications for immune evasion and oncogenesis. Viruses. 2018;10(2):82.
   PubMed Web of Science ®Google Scholar
• Barbosa MS, Edmonds C, Fisher C, et al. The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J. 1990;9(1):153–160.
   PubMed Web of Science ®Google Scholar
• Boulet G, Horvath C, Vanden Broeck D, Sahebali S, Bogers J. Human papillomavirus: E6 and E7 oncogenes. Int J Biochem Cell Biol. 2007;39(11):2006–2011.
   PubMed Web of Science ®Google Scholar
• Roman A, Munger K. The papillomavirus E7 proteins. Virology. 2013;445(1–2):138–168.
   PubMed Web of Science ®Google Scholar
• Phelps WC, Yee CL, Munger K, Howley PM. The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell. 1988;53(4):539–547.
   PubMed Web of Science ®Google Scholar
• Liu X, Clements A, Zhao K, Marmorstein R. Structure of the human papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. J Biol Chem. 2006;281(1):578–586.
   PubMed Web of Science ®Google Scholar
• Corteggio A, Altamura G, Roperto F, Borzacchiello G. Bovine papillomavirus E5 and E7 oncoproteins in naturally occurring tumors: are two better than one? Infect Agents Cancer. 2013;8(1):1.
   PubMed Web of Science ®Google Scholar
• Giarre M, Caldeira S, Malanchi I, et al. Induction of pRb degradation by the human papillomavirus type 16 E7 protein is essential to efficiently overcome p16INK4a-imposed G1 cell cycle Arrest. J Virol. 2001;75(10):4705–4712.
   PubMed Web of Science ®Google Scholar
• Albert E, Laimins L. Regulation of the human papillomavirus life cycle by DNA damage repair pathways and epigenetic factors. Viruses. 2020;12(7).
   Web of Science ®Google Scholar
• Mac M, Moody CA. Epigenetic regulation of the human papillomavirus life cycle. Pathogens. 2020;9(6):744.
   PubMed Web of Science ®Google Scholar
• Burley M, Roberts S, Parish JL. Epigenetic regulation of human papillomavirus transcription in the productive virus life cycle. Semin Immunopathol. 2020;42(2):159–171.
   PubMed Web of Science ®Google Scholar
• Stubenrauch F, Laimins LA. Human papillomavirus life cycle: active and latent phases. Semin Cancer Biol. 1999;9(6):379–386.
   PubMed Web of Science ®Google Scholar
• Netea MG, Schlitzer A, Placek K, Joosten LAB, Schultze JL. Innate and adaptive immune memory: an evolutionary continuum in the host’s response to pathogens. Cell Host Microbe. 2019;25(1):13–26.
   PubMed Web of Science ®Google Scholar
• Arango DG, Descoteaux A. Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol. 2014;5:491.
   PubMed Web of Science ®Google Scholar
• McComb S, Thiriot A, Akache B, Krishnan L, Stark F. Introduction to the Immune System. Methods Mol Biol. 2019;2024:1–24.
   PubMedGoogle Scholar
• Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov. 2007;6(5):404–414.
   PubMed Web of Science ®Google Scholar
• de Souza AP, Bonorino C. Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses. Expert Rev Anticancer Ther. 2009;9(9):1317–1332.
   PubMed Web of Science ®Google Scholar
• Gubin MM, Ward JP, Noguchi T, et al. Tumor-specific mutant antigens in cancer immunotherapy. Cancer Immunol Res. 2016;4(11). doi:10.1158/2326-6066.IMM2016-A001
   Web of Science ®Google Scholar
• Gubin MM, Zhang XL, Schuster H, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515(7528):577.
   PubMed Web of Science ®Google Scholar
• Fang S, Lisiero D, Liau L, Prins R. Epigenetic regulation of tumor-associated antigens enhances immunotherapy by sensitizing murine glioma cells to cell death by tumor-specific CD8+T cells. Neuro-Oncology. 2008;10(5):811.
   Web of Science ®Google Scholar
• Hui KM, Kim BS. Tumor-specific immunity induced by somatic hybrids.4. relationship between immunogenicity and expression of surface tumor-associated antigens. Cell Immunol. 1984;87(2):591–600.
   PubMed Web of Science ®Google Scholar
• Wagner S, Mullins CS, Linnebacher M. Colorectal cancer vaccines: tumor-associated antigens vs neoantigens. World J Gastroenterol. 2018;24(48):5418–5432.
   PubMed Web of Science ®Google Scholar
• Stark JM, Tibbitt CA, Coquet JM. The metabolic requirements of Th2 cell differentiation. Front Immunol. 2019;10:2318.
   PubMed Web of Science ®Google Scholar
• Lin C-N, Chien C-Y, Chung H-C. Are friends or foes? New strategy for head and neck squamous cell carcinoma treatment via Immune regulation. Int J Head Neck Sci. 2017;1(2):105–113.
   Google Scholar
• Yang A, Farmer E, Wu TC, Hung CF. Perspectives for therapeutic HPV vaccine development. J Biomed Sci. 2016;23(1):75.
   PubMed Web of Science ®Google Scholar
• van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJM. Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer. 2016;16(4):219–233.
   PubMed Web of Science ®Google Scholar
• Malonis RJ, Lai JR, Vergnolle O. Peptide-based vaccines: current progress and future challenges. Chem Rev. 2020;120(6):3210–3229.
   PubMed Web of Science ®Google Scholar
• Gatti-Mays ME, Redman JM, Collins JM, Bilusic M. Cancer vaccines: enhanced immunogenic modulation through therapeutic combinations. Hum Vaccin Immunother. 2017;13(11):2561–2574. doi:10.1080/21645515.2017.1364322
   PubMed Web of Science ®Google Scholar
• Vici P, Pizzuti L, Mariani L, et al. Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. Expert Rev Vaccines. 2016;15(10):1327–1336. doi:10.1080/14760584.2016.1176533
   PubMed Web of Science ®Google Scholar
• Skwarczynski M, Toth I. Peptide-based subunit nanovaccines. Curr Drug Deliv. 2011;8(3):282–289. doi:10.2174/156720111795256192
   PubMed Web of Science ®Google Scholar
• Hussein WM, Skwarczynski M, Istvan T. An isodipeptide building block for microwave-assisted solid-phase synthesis of difficult sequence-containing peptides. Methods Mol Biol. 2020;2103:139–150.
   PubMedGoogle Scholar
• Hussein WM, Liu T-Y, Toth I, Skwarczynski M. Microwave-assisted synthesis of difficult sequence-containing peptides using the isopeptide method. Org Biomol Chem. 2013;11(14):2370–2376. doi:10.1039/c3ob00030c
   PubMed Web of Science ®Google Scholar
• Andreatta M, Nielsen M. Bioinformatics tools for the prediction of T-cell epitopes. Methods Mol Biol. 2018;1785:269–281.
   PubMedGoogle Scholar
• Sharma G, Rive CM, Holt RA. Rapid selection and identification of functional CD8+ T cell epitopes from large peptide-coding libraries. Nat Commun. 2019;10(1):4553. doi:10.1038/s41467-019-12444-7
   PubMed Web of Science ®Google Scholar
• Wieczorek M, Abualrous ET, Sticht J, et al. Major histocompatibility complex (MHC) class I and MHC class II proteins: conformational plasticity in antigen presentation. Front Immunol. 2017;8. doi:10.3389/fimmu.2017.00292
   Web of Science ®Google Scholar
• Kaliamurthi S, Selvaraj G, Junaid M, et al. Cancer immunoinformatics: a promising era in the development of peptide vaccines for human papillomavirus-induced cervical cancer. Curr Pharm Des. 2019;24(32):3791–3817. doi:10.2174/1381612824666181106094133
   Web of Science ®Google Scholar
• Liao WWP, Arthur JW. Predicting peptide binding to major histocompatibility complex molecules. Autoimmun Rev. 2011;10(8):469–473. doi:10.1016/j.autrev.2011.02.003
   PubMed Web of Science ®Google Scholar
• Liu W, Tang H, Li L, et al. Peptide-based therapeutic cancer vaccine: current trends in clinical application. Cell Prolif. 2021;54(5):e13025–e13025. doi:10.1111/cpr.13025
   PubMed Web of Science ®Google Scholar
• Lundegaard C, Hoof I, Lund O, Nielsen M. State of the art and challenges in sequence based T-cell epitope prediction. Immunome Res. 2010;6(2):S3. doi:10.1186/1745-7580-6-S2-S3
   PubMedGoogle Scholar
• Kaliamurthi S, Selvaraj G, Kaushik AC, Gu K-R, Wei D-Q. Designing of CD8(+) and CD8(+)-overlapped CD4(+) epitope vaccine by targeting late and early proteins of human papillomavirus. Biol Targets Ther. 2018;12:107–125.
   PubMed Web of Science ®Google Scholar
• Kaliamurthi S, Selvaraj G, Chinnasamy S, et al. Exploring the papillomaviral proteome to identify potential candidates for a chimeric vaccine against cervix papilloma using immunomics and computational structural vaccinology. Viruses. 2019;11(1):63. doi:10.3390/v11010063
   PubMed Web of Science ®Google Scholar
• Ma W, Melief CJM, van der Burg SH. van der Burg SH. Control of immune escaped human papilloma virus is regained after therapeutic vaccination. Curr Opin Virol. 2017;23:16–22. doi:10.1016/j.coviro.2017.02.005
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang H, Yang Y, et al. Mannose-modified liposome co-delivery of human papillomavirus type 16 E7 peptide and CpG oligodeoxynucleotide adjuvant enhances antitumor activity against established large TC-1 grafted tumors in mice. Int J Nanomedicine. 2020;15:9571–9586. doi:10.2147/IJN.S275670
   PubMed Web of Science ®Google Scholar
• Liu T-Y, Hussein WM, Jia Z, et al. Self-adjuvanting polymer–peptide conjugates as therapeutic vaccine candidates against cervical cancer. Biomacromolecules. 2013;14(8):2798–2806. doi:10.1021/bm400626w
   PubMed Web of Science ®Google Scholar
• Tindle RW, Fernando GJ, Sterling JC, Frazer IH. A ”public” T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. PNAS. 1991;88(13):5887–5891. doi:10.1073/pnas.88.13.5887
   PubMed Web of Science ®Google Scholar
• Bahmani B, Amini-bayat Z, Ranjbar MM, Bakhtiari N, Zarnani A-H. HPV16-E7 protein T cell epitope prediction and global therapeutic peptide vaccine design based on human leukocyte antigen frequency: an in-silico study. Int J Pept Res Ther. 2021;27(1):365–378. doi:10.1007/s10989-020-10089-5
   PubMed Web of Science ®Google Scholar
• de Oliveira LMF, Morale MG, Chaves AAM, et al. Design, immune responses and anti-tumor potential of an HPV16 E6E7 multi-epitope vaccine. PLoS One. 2015;10(9):e0138686–e0138686. doi:10.1371/journal.pone.0138686
   PubMed Web of Science ®Google Scholar
• Cordeiro MN, De Lima RDCP, Paolini F, et al. Current research into novel therapeutic vaccines against cervical cancer. Expert Review of Anticancer Therapy. 2018;18(4):365–376. doi:10.1080/14737140.2018.1445527
   PubMed Web of Science ®Google Scholar
• Morishima S, Akatsuka Y, Nawa A, et al. Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-γ on the presentation of a cryptic epitope. Int J Cancer. 2007;120(3):594–604. doi:10.1002/ijc.22312
   PubMed Web of Science ®Google Scholar
• Hussein WM, Liu T-Y, Jia Z, et al. Multiantigenic peptide–polymer conjugates as therapeutic vaccines against cervical cancer. Bioorg Med Chem. 2016;24(18):4372–4380. doi:10.1016/j.bmc.2016.07.036
   PubMed Web of Science ®Google Scholar
• Manuri PR, Nehete B, Nehete PN, et al. Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. Vaccine. 2007;25(17):3302–3310. doi:10.1016/j.vaccine.2007.01.010
   PubMed Web of Science ®Google Scholar
• Nguyen CT, Hong SH, Sin J-I, et al. Flagellin enhances tumor-specific CD8+ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model. Vaccine. 2013;31(37):3879–3887. doi:10.1016/j.vaccine.2013.06.054
   PubMed Web of Science ®Google Scholar
• Namvar A, Panahi HA, Agi E, Bolhassani A. Development of HPV16,18,31,45 E5 and E7 peptides-based vaccines predicted by immunoinformatics tools. Biotechnol Lett. 2020;42(3):403–418. doi:10.1007/s10529-020-02792-6
   PubMed Web of Science ®Google Scholar
• Kumar A, Yadav IS, Hussain S, Das BC, Bharadwaj M. Identification of immunotherapeutic epitope of E5 protein of human papillomavirus-16: an in silico approach. Biologicals. 2015;43(5):344–348. doi:10.1016/j.biologicals.2015.07.002
   PubMed Web of Science ®Google Scholar
• Cordeiro MN, Paolini F, Massa S, et al. Anti-tumor effects of genetic vaccines against HPV major oncogenes. Hum Vaccin Immunother. 2015;11(1):45–52. doi:10.4161/hv.34303
   PubMed Web of Science ®Google Scholar
• Testa JS, Philip R. Role of T-cell epitope-based vaccine in prophylactic and therapeutic applications. Future Virol. 2012;7(11):1077–1088. doi:10.2217/fvl.12.108
   PubMed Web of Science ®Google Scholar
• Alexander J, Sidney J, Southwood S, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity. 1994;1(9):751–761. doi:10.1016/S1074-7613(94)80017-0
   PubMed Web of Science ®Google Scholar
• Muderspach L, Wilczynski S, Roman L, et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res. 2000;6(9):3406–3416.
   PubMed Web of Science ®Google Scholar
• Ressing ME, van Driel WJ, Brandt RMP, et al. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother. 2000;23(2):255–266. doi:10.1097/00002371-200003000-00010
   PubMed Web of Science ®Google Scholar
• van Driel WJ, Ressing ME, Kenter GG, et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I–II trial. Eur J Cancer. 1999;35(6):946–952. doi:10.1016/S0959-8049(99)00048-9
   PubMed Web of Science ®Google Scholar
• Jacoberger-Foissac C, Saliba H, Seguin C, et al. Optimization of peptide-based cancer vaccine compositions, by sequential screening, using versatile liposomal platform. Int J Pharm. 2019;562:342–350. doi:10.1016/j.ijpharm.2019.03.002
   PubMed Web of Science ®Google Scholar
• Hussein WM, Liu T-Y, Skwarczynski M, Toth I. Toll-like receptor agonists: a patent review (2011 – 2013). Expert Opin Ther Pat. 2014;24(4):453–470. doi:10.1517/13543776.2014.880691
   PubMed Web of Science ®Google Scholar
• Kawasaki T, Kawai T. Toll-Like receptor signaling pathways. Front Immunol. 2014;5:461. doi:10.3389/fimmu.2014.00461
   PubMed Web of Science ®Google Scholar
• Del Giudice G, Rappuoli R, Didierlaurent AM. Correlates of adjuvanticity: a review on adjuvants in licensed vaccines. Semin Immunol. 2018;39:14–21. doi:10.1016/j.smim.2018.05.001
   PubMed Web of Science ®Google Scholar
• Naud PS, Roteli-Martins CM, De Carvalho NS, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine. Hum Vaccin Immunother. 2014;10(8):2147–2162. doi:10.4161/hv.29532
   PubMed Web of Science ®Google Scholar
• López-Fauqued M, Zima J, Angelo M-G, Stegmann J-U. Results on exposure during pregnancy from a pregnancy registry for AS04-HPV-16/18 vaccine. Vaccine. 2017;35(40):5325–5330. doi:10.1016/j.vaccine.2017.08.042
   PubMed Web of Science ®Google Scholar
• Motavalli Khiavi F, Arashkia A, Golkar M, et al. A dual-type L2 11-88 peptide from HPV types 16/18 formulated in Montanide ISA 720 induced strong and balanced Th1/Th2 immune responses, associated with high titers of broad spectrum cross-reactive antibodies in vaccinated mice. J Immunol Res. 2018;2018:9464186. doi:10.1155/2018/9464186
   PubMed Web of Science ®Google Scholar
• Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman DM. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines. 2011;10(4):499–511. doi:10.1586/erv.10.174
   PubMed Web of Science ®Google Scholar
• Khan MJ, Svedberg A, Singh AA, Ansari MS, Karim Z. Chapter 13 - use of nanostructured polymer in the delivery of drugs for cancer therapy. In: Swain SK, Jawaid M, editors. Nanostructured Polymer Composites for Biomedical Applications. Elsevier; 2019:261–276.
   Google Scholar
• Embgenbroich M, Burgdorf S. Current concepts of antigen cross-presentation. Front Immunol. 2018;9:1643. doi:10.3389/fimmu.2018.01643
   PubMed Web of Science ®Google Scholar
• Azmi F, Ahmad Fuaad AAH, Skwarczynski M, Toth I. Recent progress in adjuvant discovery for peptide-based subunit vaccines. Hum Vaccin Immunother. 2014;10(3):778–796. doi:10.4161/hv.27332
   PubMed Web of Science ®Google Scholar
• Aucouturier J, Dupuis L, Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine. 2001;19(17–19):2666–2672. doi:10.1016/S0264-410X(00)00498-9
   PubMed Web of Science ®Google Scholar
• Cuzzubbo S, Mangsbo S, Nagarajan D, et al. Cancer vaccines: adjuvant potency, importance of age, lifestyle, and treatments. Front Immunol. 2020;11:615240. doi:10.3389/fimmu.2020.615240
   PubMed Web of Science ®Google Scholar
• Khong H, Overwijk WW. Adjuvants for peptide-based cancer vaccines. J Immunother Cancer. 2016;4(1):56. doi:10.1186/s40425-016-0160-y
   PubMed Web of Science ®Google Scholar
• Zhou Y, Banday AH, Hruby VJ, Cai M. Development of N-acetylated dipalmitoyl-S-glyceryl cysteine analogs as efficient TLR2/TLR6 agonists. Molecules. 2019;24(19):3512. doi:10.3390/molecules24193512
   PubMed Web of Science ®Google Scholar
• Moyle PM, Dai W, Liu T-Y, et al. Combined synthetic and recombinant techniques for the development of lipoprotein-based, self-adjuvanting vaccines targeting human papillomavirus type-16 associated tumors. Bioorganic Med Chem Lett. 2015;25(23):5570–5575. doi:10.1016/j.bmcl.2015.10.049
   PubMed Web of Science ®Google Scholar
• Hussein WM, Liu T-Y, Maruthayanar P, et al. Double conjugation strategy to incorporate lipid adjuvants into multiantigenic vaccines. Chem Sci. 2016;7(3):2308–2321. doi:10.1039/C5SC03859F
   PubMed Web of Science ®Google Scholar
• Hussein WM, Mukaida S, Liu TY, Toth I. Fluorinated lipids conjugated to peptide antigens do not induce immune responses against cervical cancer. Vaccin Res Open J. 2017;1(1):39–44.
   Google Scholar
• Hussein WM, Mukaida S, Azmi F, et al. Comparison of fluorinated and nonfluorinated lipids in self-adjuvanting delivery systems for peptide-based vaccines. ACS Med Chem Lett. 2017;8(2):227–232. doi:10.1021/acsmedchemlett.6b00453
   PubMed Web of Science ®Google Scholar
• Mousavi T, Sattari Saravi S, Valadan R, et al. Different types of adjuvants in prophylactic and therapeutic human papillomavirus vaccines in laboratory animals: a systematic review. Arch Virol. 2020;165(2):263–284. doi:10.1007/s00705-019-04479-4
   PubMed Web of Science ®Google Scholar
• Domingos-Pereira S, Decrausaz L, Derré L, et al. Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice. Mucosal Immunol. 2013;6(2):393–404. doi:10.1038/mi.2012.83
   PubMed Web of Science ®Google Scholar
• Wick DA, Martin SD, Nelson BH, Webb JR. Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C). Vaccine. 2011;29(5):984–993. doi:10.1016/j.vaccine.2010.11.036
   PubMed Web of Science ®Google Scholar
• Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature. 2001;410(6832):1099–1103. doi:10.1038/35074106
   PubMed Web of Science ®Google Scholar
• Smith KD, Andersen-Nissen E, Hayashi F, et al. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol. 2003;4(12):1247–1253. doi:10.1038/ni1011
   PubMed Web of Science ®Google Scholar
• Chen W, Jiang M, Yu W, et al. CpG-based nanovaccines for cancer immunotherapy. Int J Nanomedicine. 2021;16:5281–5299. doi:10.2147/IJN.S317626
   PubMed Web of Science ®Google Scholar
• Scheiermann J, Klinman DM. Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer. Vaccine. 2014;32(48):6377–6389. doi:10.1016/j.vaccine.2014.06.065
   PubMed Web of Science ®Google Scholar
• Chen Y-F, Lin C-W, Tsao Y-P, Chen S-L. Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice. J Virol. 2004;78(3):1333–1343. doi:10.1128/JVI.78.3.1333-1343.2004
   PubMed Web of Science ®Google Scholar
• Yang Y, Che Y, Zhao Y, Wang X. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo. Int Immunopharmacol. 2019;69:279–288. doi:10.1016/j.intimp.2019.01.024
   PubMed Web of Science ®Google Scholar
• Marasini N, Giddam AK, Khalil ZG, et al. Double adjuvanting strategy for peptide-based vaccines: trimethyl chitosan nanoparticles for lipopeptide delivery. Nanomedicine. 2016;11(24):3223–3235. doi:10.2217/nnm-2016-0291
   PubMed Web of Science ®Google Scholar
• Pati R, Shevtsov M, Sonawane A. Nanoparticle vaccines against infectious diseases. Front Immunol. 2018;9:2224.
   PubMed Web of Science ®Google Scholar
• Zhao L, Seth A, Wibowo N, et al. Nanoparticle vaccines. Vaccine. 2014;32(3):327–337.
   PubMed Web of Science ®Google Scholar
• Ma W, Chen M, Kaushal S, et al. PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses. Int J Nanomedicine. 2012;7:1475–1487.
   PubMed Web of Science ®Google Scholar
• Demento SL, Siefert AL, Bandyopadhyay A, Sharp FA, Fahmy TM. Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines. Trends Biotechnol. 2011;29(6):294–306.
   PubMed Web of Science ®Google Scholar
• Zhao G, Chandrudu S, Skwarczynski M, Toth I. The application of self-assembled nanostructures in peptide-based subunit vaccine development. Eur Polym J. 2017;93:670–681.
   PubMed Web of Science ®Google Scholar
• Boles MA, Ling D, Hyeon T, Talapin DV. The surface science of nanocrystals. Nat Mater. 2016;15(2):141–153.
   PubMed Web of Science ®Google Scholar
• Choudhary S, Kusum Devi V. Potential of nanotechnology as a delivery platform against tuberculosis: current research review. J Control Release. 2015;202:65–75.
   PubMed Web of Science ®Google Scholar
• Skwarczynski M, Zhao G, Boer JC, et al. Poly(amino acids) as a potent self-adjuvanting delivery system for peptide-based nanovaccines. Sci Adv. 2020;6(5):eaax2285.
   PubMed Web of Science ®Google Scholar
• Mir M, Ahmed N, Rehman AU. Recent applications of PLGA based nanostructures in drug delivery. Colloids Surf B. 2017;159:217–231.
   PubMed Web of Science ®Google Scholar
• Win KY, Feng SS. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005;26(15):2713–2722.
   PubMed Web of Science ®Google Scholar
• Nevagi RJ, Skwarczynski M, Toth I. Polymers for subunit vaccine delivery. Eur Polym J. 2019;114:397–410.
   Web of Science ®Google Scholar
• Mehdi K, Mohsen M, Naser Mohammadpour D, Mohsen M, Alireza M. Nanoparticles and vaccine development. Pharm Nanotechnol. 2020;8(1):6–21.
   PubMedGoogle Scholar
• Malik A, Gupta M, Gupta V, Gogoi H, Bhatnagar R. Novel application of trimethyl chitosan as an adjuvant in vaccine delivery. Int J Nanomedicine. 2018;13:7959–7970.
   PubMed Web of Science ®Google Scholar
• Martău GA, Mihai M, Vodnar DC. The use of chitosan, alginate, and pectin in the biomedical and food sector—biocompatibility, bioadhesiveness, and biodegradability. Polymers. 2019;11:11.
   Web of Science ®Google Scholar
• Zhao L, Skwarczynski M, Toth I. Polyelectrolyte-based platforms for the delivery of peptides and proteins. ACS Biomater Sci Eng. 2019;5(10):4937–4950.
   PubMed Web of Science ®Google Scholar
• Sun B, Yu S, Zhao D, et al. Polysaccharides as vaccine adjuvants. Vaccine. 2018;36(35):5226–5234.
   PubMed Web of Science ®Google Scholar
• Li X, Min M, Du N, et al. Chitin, chitosan, and glycated chitosan regulate immune responses: the novel adjuvants for cancer vaccine. Clin Dev Immunol. 2013;2013:387023.
   PubMedGoogle Scholar
• Silva AL, Soema PC, Slutter B, Ossendorp F, Jiskoot W. PLGA particulate delivery systems for subunit vaccines: linking particle properties to immunogenicity. Hum Vaccin Immunother. 2016;12(4):1056–1069.
   PubMed Web of Science ®Google Scholar
• Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011;3(3):1377–1397.
   PubMed Web of Science ®Google Scholar
• Gutjahr A, Phelip C, Coolen AL, et al. Biodegradable polymeric nanoparticles-based vaccine adjuvants for lymph nodes targeting. Vaccines. 2016;4(4):34.
   PubMed Web of Science ®Google Scholar
• Marasini N, Khalil ZG, Giddam AK, et al. Lipid core peptide/poly(lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against Group A streptococcus. Int J Pharm. 2016;513(1):410–420.
   PubMed Web of Science ®Google Scholar
• Ghassemi AH, van Steenbergen MJ, Talsma H, et al. Preparation and characterization of protein loaded microspheres based on a hydroxylated aliphatic polyester, poly(lactic-co-hydroxymethyl glycolic acid). J Control Release. 2009;138(1):57–63.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Huang W, Yuan M, et al. Employing ATP as a new adjuvant promotes the induction of robust antitumor cellular immunity by a PLGA nanoparticle vaccine. ACS Appl Mater Interfaces. 2020;12(49):54399–54414.
   PubMed Web of Science ®Google Scholar
• Rahimian S, Fransen MF, Kleinovink JW, et al. Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation. J Control Release. 2015;203:16–22.
   PubMed Web of Science ®Google Scholar
• Hilgers LAT, Ghenne L, Nicolas I, et al. Alkyl-polyacrylate esters are strong mucosal adjuvants. Vaccine. 2000;18(28):3319–3325.
   PubMed Web of Science ®Google Scholar
• Skwarczynski M, Zaman M, Urbani CN, et al. Polyacrylate dendrimer nanoparticles: a self-adjuvanting vaccine delivery system. Angew Chem Int Ed. 2010;49(33):5742–5745.
   PubMed Web of Science ®Google Scholar
• Liu TY, Hussein WM, Giddam AK, et al. Polyacrylate-based delivery system for self-adjuvanting anticancer peptide vaccine. J Med Chem. 2015;58(2):888–896.
   PubMed Web of Science ®Google Scholar
• Liu TY, Giddam AK, Hussein WM, et al. Self-adjuvanting therapeutic peptide-based vaccine induce CD8+ cytotoxic T lymphocyte responses in a murine human papillomavirus tumor model. Curr Drug Deliv. 2015;12(1):3–8.
   PubMed Web of Science ®Google Scholar
• Hussein WM, Choi PM, Zhang C, et al. Investigating the affinity of poly tert-butyl acrylate toward toll-like receptor 2. AIMS Allergy Immunol. 2018;2(3):141–147.
   Web of Science ®Google Scholar
• Khongkow MLT, Bartlett S, Hussein WM, et al. Liposomal formulation of polyacrylate-peptide conjugate as a new vaccine candidate against cervical cancer. Prec Namomed. 2018;1(3):183–193.
   Google Scholar
• Truong HH,;, Hussein WM, Liu T, et al. Self-adjuvanting peptide vaccines against cervical cancer. Vaccin Res Open J. 2019;1(1):81–89.
   Google Scholar
• Rad-Malekshahi M, Fransen MF, Krawczyk M, et al. Self-assembling peptide epitopes as novel platform for anticancer vaccination. Mol Pharm. 2017;14(5):1482–1493.
   PubMed Web of Science ®Google Scholar
• Ma X, Wang Y, Zhao T, et al. Ultra-pH-sensitive nanoprobe library with broad pH tunability and fluorescence emissions. J Am Chem Soc. 2014;136(31):11085–11092.
   PubMed Web of Science ®Google Scholar
• Luo M, Wang H, Wang Z, et al. A STING-activating nanovaccine for cancer immunotherapy. Nat Nanotechnol. 2017;12(7):648–654.
   PubMed Web of Science ®Google Scholar
• Luo M, Liu Z, Zhang X, et al. Synergistic STING activation by PC7A nanovaccine and ionizing radiation improves cancer immunotherapy. J Control Release. 2019;300:154–160.
   PubMed Web of Science ®Google Scholar
• Abu Lila AS, Ishida T. Liposomal delivery systems: design optimization and current applications. Biol Pharm Bull. 2017;40(1):1–10.
   PubMed Web of Science ®Google Scholar
• Nisini R, Poerio N, Mariotti S, De Santis F, Fraziano M. The multirole of liposomes in therapy and prevention of infectious diseases. Front Immunol. 2018;9:155.
   PubMed Web of Science ®Google Scholar
• Daraee H, Etemadi A, Kouhi M, Alimirzalu S, Akbarzadeh A. Application of liposomes in medicine and drug delivery. Artif Cells Nanomed Biotechnol. 2016;44(1):381–391.
   PubMed Web of Science ®Google Scholar
• Khairunnisa Abdul G, Ashwini Kumar G, Mehfuz Z, Mariusz S, Istvan T. Liposomes as nanovaccine delivery systems. Curr Top Med Chem. 2014;14(9):1194–1208.
   PubMed Web of Science ®Google Scholar
• Giddam AK, Zaman M, Skwarczynski M, Toth I. Liposome-based delivery system for vaccine candidates: constructing an effective formulation. Nanomedicine. 2012;7(12):1877–1893.
   PubMed Web of Science ®Google Scholar
• Yan W, Chen W, Huang L. Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol Immunol. 2007;44(15):3672–3681.
   PubMed Web of Science ®Google Scholar
• Chen W, Yan W, Huang L. A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunol Immunother. 2008;57(4):517–530.
   PubMed Web of Science ®Google Scholar
• Chen W, Huang L. Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine. Mol Pharm. 2008;5(3):464–471.
   PubMed Web of Science ®Google Scholar
• Vasievich EA, Chen W, Huang L. Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine. Cancer Immunol Immunother. 2011;60(5):629–638.
   PubMed Web of Science ®Google Scholar
• He X, Zhou S, Quinn B, et al. HPV-associated tumor eradication by vaccination with synthetic short peptides and particle-forming liposomes. Small. 2021;17(11):2007165.
   Web of Science ®Google Scholar
• Daftarian PM, Mansour M, Pohajdak B, et al. Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax encapsulated CTL/T helper peptides. J Transl Med. 2007;5:26.
   PubMed Web of Science ®Google Scholar
• Weir GM, Hrytsenko O, Quinton T, et al. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide. J Immunother Cancer. 2016;4:68.
   PubMed Web of Science ®Google Scholar
• Weir GM, Hrytsenko O, Stanford MM, et al. Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response. OncoImmunology. 2014;3(8):e953407.
   PubMed Web of Science ®Google Scholar
• Arevalo MT, Wong TM, Ross TM. Expression and purification of virus-like particles for vaccination. J Vis Exp. 2016;112:e54041.
   Google Scholar
• Mohsen MO, Speiser DE, Knuth A, Bachmann MF. Virus-like particles for vaccination against cancer. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020;12(1):e1579.
   PubMed Web of Science ®Google Scholar
• Nooraei S, Bahrulolum H, Hoseini ZS, et al. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J Nanobiotechnol. 2021;19(1):59.
   PubMed Web of Science ®Google Scholar
• Müller M, Zhou J, Reed TD, et al. Chimeric papillomavirus-like particles. Virology. 1997;234(1):93–111.
   PubMed Web of Science ®Google Scholar
• Schäfer K, Müller M, Faath S, et al. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. Int J Cancer. 1999;81(6):881–888.
   PubMed Web of Science ®Google Scholar
• Kaufmann AM, Nieland JD, Jochmus I, et al. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer. 2007;121(12):2794–2800.
   PubMed Web of Science ®Google Scholar
• Freyschmidt EJ, Alonso A, Hartmann G, Gissmann L. Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol. Antivir Ther. 2004;9(4):479–489.
   PubMed Web of Science ®Google Scholar
• Monroy-García A, Gómez-Lim MA, Weiss-Steider B, et al. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model. Arch Virol. 2014;159(2):291–305.
   PubMed Web of Science ®Google Scholar
• Jemon K, Young V, Wilson M, et al. An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy. PLoS One. 2013;8(6):e66866.
   PubMed Web of Science ®Google Scholar
• Martin Caballero J, Garzón A, González-Cintado L, et al. Chimeric infectious bursal disease virus-like particles as potent vaccines for eradication of established HPV-16 E7–dependent tumors. PLoS One. 2013;7(12):e52976.
   Web of Science ®Google Scholar
• Chu X, Yang L, Long Q, et al. Chimeric HBcAg virus-like particles presenting a HPV 16 E7 epitope significantly suppressed tumor progression through preventive or therapeutic immunization in a TC-1-grafted mouse model. Int J Nanomedicine. 2016;11:2417–2429.
   PubMed Web of Science ®Google Scholar
• Gomes AC, Flace A, Saudan P, et al. Adjusted particle size eliminates the need of linkage of antigen and adjuvants for appropriated T cell responses in virus-like particle-based vaccines. Front Immunol. 2017;8:226.
   PubMed Web of Science ®Google Scholar
• Shi Y, Liu CH, Roberts AI, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don’t know. Cell Res. 2006;16(2):126–133.
   PubMed Web of Science ®Google Scholar
• Simmons AD, Li B, Gonzalez-Edick M, et al. GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action. Cancer Immunol Immunother. 2007;56(10):1653–1665.
   PubMed Web of Science ®Google Scholar
• Tang J, Yin R, Tian Y, et al. A novel self-assembled nanoparticle vaccine with HIV-1 Tat49-57/HPV16 E749-57 fusion peptide and GM-CSF DNA elicits potent and prolonged CD8+ T cell-dependent anti-tumor immunity in mice. Vaccine. 2012;30(6):1071–1082.
   PubMed Web of Science ®Google Scholar
• Ressing ME, van Driel WJ, Celis E, et al. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res. 1996;56(3):582–588.
   PubMed Web of Science ®Google Scholar
• Kenter GG, Welters MJ, Valentijn AR, et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res. 2008;14(1):169–177.
   PubMed Web of Science ®Google Scholar
• Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361(19):1838–1847.
   PubMed Web of Science ®Google Scholar
• de Vos van Steenwijk PJ, Ramwadhdoebe TH, Löwik MJG, et al. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. Cancer Immunol Immunother. 2012;61(9):1485–1492.
   PubMed Web of Science ®Google Scholar
• van Poelgeest MIE, Welters MJP, van Esch EMG, et al. HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med. 2013;11:88.
   PubMed Web of Science ®Google Scholar
• de Vos van Steenwijk PJ, van Poelgeest MIE, Ramwadhdoebe TH, et al. The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study. Cancer Immunol Immunother. 2014;63(2):147–160.
   PubMed Web of Science ®Google Scholar
• Hasegawa K, Ikeda Y, Kunugi Y, et al. Phase I study of multiple epitope peptide vaccination in patients with recurrent or persistent cervical cancer. J Immunother. 2018;41(4):201–207.
   PubMed Web of Science ®Google Scholar
• Ohno S, Okuyama R, Aruga A, Sugiyama H, Yamamoto M. Phase I trial of Wilms’ tumor 1 (WT1) peptide vaccine with GM-CSF or CPG in patients with solid malignancy. Anticancer Res. 2012;32(6):2263.
   PubMed Web of Science ®Google Scholar
• Oka Y, Tsuboi A, Oji Y, Kawase I, Sugiyama H. WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol. 2008;20(2):211–220.
   PubMed Web of Science ®Google Scholar
• Miyatake T, Ueda Y, Morimoto A, et al. WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial. J Cancer Res Clin Oncol. 2013;139(3):457–463.
   PubMed Web of Science ®Google Scholar
• Reuschenbach M, Rafiyan M, Pauligk C, et al. Phase I/IIa trial targeting p16INK4a by peptide vaccination in patients with human papillomavirus-associated cancer. J Clin Oncol. 2015;33(15_suppl):e14030–e14030.
   Web of Science ®Google Scholar
• Wang X, Coleman HN, Nagarajan U, Spencer HJ, Nakagawa M. Candida skin test reagent as a novel adjuvant for a human papillomavirus peptide-based therapeutic vaccine. Vaccine. 2013;31(49):5806–5813.
   PubMed Web of Science ®Google Scholar
• Coleman HN, Greenfield WW, Stratton SL, et al. Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination. Cancer Immunol Immunother. 2016;65(5):563–573.
   PubMed Web of Science ®Google Scholar
• Nakagawa M, Coleman HN, Wang X, et al. IL-12 secretion by Langerhans cells stimulated with Candida skin test reagent is mediated by dectin-1 in some healthy individuals. Cytokine. 2014;65(2):202–209.
   PubMed Web of Science ®Google Scholar
• Greenfield WW, Stratton SL, Myrick RS, et al. A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3. Oncoimmunology. 2015;4(10):e1031439–e1031439.
   PubMed Web of Science ®Google Scholar
• Smalley Rumfield C, Pellom ST, Morillon Ii YM, Schlom J, Jochems C. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine. J Immunother Cancer. 2020;8(1):e000612.
   PubMed Web of Science ®Google Scholar
• Brewer KD, Weir GM, Dude I, et al. Unique depot formed by an oil based vaccine facilitates active antigen uptake and provides effective tumour control. J Biomed Sci. 2018;25(1):7.
   PubMed Web of Science ®Google Scholar
• Wang C, Dickie J, Sutavani RV, et al. Targeting head and neck cancer by vaccination. Front Immunol. 2018;9:830.
   PubMed Web of Science ®Google Scholar
• Domingos-Pereira S, Galliverti G, Hanahan D, Nardelli-Haefliger D. Carboplatin/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors. J Immunother Cancer. 2019;7(1):122.
   PubMed Web of Science ®Google Scholar
• Welters Marij J, van der Sluis Tetje C, van Meir H, et al. Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. Sci Transl Med. 2016;8(334):334ra352–334ra352.
   Web of Science ®Google Scholar
• Shibata T, Lieblong BJ, Sasagawa T, Nakagawa M. The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer. Cancer Treat Rev. 2019;78:8–16.
   PubMed Web of Science ®Google Scholar
• Massarelli E, William W, Johnson F, et al. Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16–related cancer: a Phase 2 clinical trial. JAMA Oncol. 2019;5(1):67–73.
   PubMed Web of Science ®Google Scholar